<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189679</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.133</org_study_id>
    <secondary_id>2019-A01255-52</secondary_id>
    <nct_id>NCT04189679</nct_id>
  </id_info>
  <brief_title>Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma</brief_title>
  <acronym>METABO-ICI</acronym>
  <official_title>: Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune checkpoints inhibitors (ICI) are becoming new standards of care for Non-Small Cell
      Lung Carcinoma (NSCLC) treatment. To date, no powerful predictive biomarker of response has
      been found.

      The investigators hypothesize that metabolomics profile could represent a potent biomarker of
      response to ICI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immune checkpoints inhibitors (ICI) are becoming new standards of care for Non-Small Cell
      Lung Carcinoma (NSCLC) treatment, both as first and second line of treatment. To date, no
      powerful predictive biomarker of response has been found. It has been recently shown that
      microbiota composition could dictate the ability of patients to respond to ICI. Since, the
      microbiota produces circulating metabolites that will subsequently act on immune system, the
      investigators hypothesized that metabolic signature, reflecting microbiota function, could
      represent a predictive biomarker of response to ICI.

      Primary objective is to identify baseline metabolic signature (metabolomics analysis by Mass
      spectrometry) associated to ICI response. Secondary objectives are to link metabolic
      signature with microbiota composition (metagenomics analysis RNA 16S) and immune profile, and
      altogether with clinic response to ICI. Profile evolution (metabolic, metagenomics and
      immune) will be also analyzed at 2-month post ICI initiation and at tumor progression, if
      any.

      In order to do so, the investigators thus plan to enroll 60 NSCLC patients treated by ICI as
      1st, 2nd or 3rd line of treatment in CHUGA in 18 months. Blood as well feces will be
      collected prior to, and at 2 month following ICI treatment initiation as well as at
      progression. Will be excluded from this study, patients that have received antibiotic or
      corticotherapy 2 or 4 weeks before ICI initiation, respectively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of the change from baseline Metabolic signature as predictive factor of the ICI response at 6 months or at the tumoral progression</measure>
    <time_frame>baseline, 6 months or tumoral progression</time_frame>
    <description>To identify the link of the change from baseline of Metabolic signature in serum (metabolomics analysis performed using a Mass spectrometry) and the ICI response at 6 months or at the tumoral progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of the link between the Meta-genomic and immune signatures and the metabolic signature at 6 months or at the tumoral progression</measure>
    <time_frame>6 months or tumoral progression</time_frame>
    <description>To identify the link between the Meta-genomic signature of intestinal flora (microbiota composition analysed by RNA 16 S) with the Immune signature in serum and the metabolic signature at 6 months or at the tumoral progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of the link between the Meta-genomic and immune signatures and ICI response at 6 months or at the tumoral progression</measure>
    <time_frame>6 months or tumoral progression</time_frame>
    <description>To identify the link between the Meta-genomic signature of intestinal flora with the Immune signature in serum and the ICI response at 6 months or at the tumoral progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the profile change of Meta-genomic signature</measure>
    <time_frame>2 months or tumoral progression</time_frame>
    <description>To describe the change from baseline of the Meta-genomic signature at 2 months or at the tumoral progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the profile change of Immune signature at 2 months or at the tumoral progression</measure>
    <time_frame>Baseline and 2 months or tumoral progression</time_frame>
    <description>To describe the change from baseline of the Immune signature at 2 months or at the tumoral progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of the link between the profile change of meta-genomic signature and the ICI response at 2 months or at the tumoral progression</measure>
    <time_frame>Baseline and (2 months or tumoral progression)</time_frame>
    <description>To identify the link between the profile change from baseline of meta-genomic signature and the ICI response at 2 months or at the tumoral progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of change of immune signature and the ICI response at 2 months or at the tumoral progression</measure>
    <time_frame>Baseline and (2 months or tumoral progression)</time_frame>
    <description>To identify the link between the profile change from baseline of immune signature and the ICI response at 2 months or at the tumoral progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of overall survival under ICI at 6 months or at the tumoral progression</measure>
    <time_frame>6 months or tumoral progression</time_frame>
    <description>To describe of the overall survival under ICI at 6 months or at the tumoral progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the survival without progression under ICI at 6 months or at the tumoral progression</measure>
    <time_frame>6 months or tumoral progression</time_frame>
    <description>To describe the survival without progression under ICI at 6 months or at the tumoral progression</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>First line</arm_group_label>
    <description>20 patients in first line of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second or third line</arm_group_label>
    <description>40 patients in second and third line of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immune signature in serum associated to the metabolic signature</intervention_name>
    <description>Immune signature in serum associated to the metabolic signature</description>
    <arm_group_label>First line</arm_group_label>
    <arm_group_label>Second or third line</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Meta-genomic signature of intestinal flora</intervention_name>
    <description>Meta-genomic signature of intestinal flora</description>
    <arm_group_label>First line</arm_group_label>
    <arm_group_label>Second or third line</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Meta-genomic signature of intestinal flora
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study cohort will include NSCLC patients treated by ICI as 1st, 2nd or 3rd line of
        treatment in Grenoble University Hospital (France) in 18 months. 60 NSCLC patients are
        anticipated to be enrolled in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NSCLC diagnosis

          -  Patient treated by a ICI in first, second or third line of treatment, or by the
             combination of chemotherapy and IPCI in first line of treatment

          -  Patient with at least one measurable lesion as defined by RECIST

        Exclusion Criteria:

          -  Patient treated with antibiotic treatment within 2 weeks before the start of ICI or
             corticosteroids (&gt;20 mg per day) within 4 weeks before the start of ICI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Claire Toffart, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dalil Hannani, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medicine University, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Claire TOFFART, Dr</last_name>
    <phone>+33(0)4 76 76 75 75</phone>
    <email>atoffart@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital, Grenoble</name>
      <address>
        <city>La Tronche</city>
        <state>Is√®re</state>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Tchikladze</last_name>
      <phone>+33 (0) 4 76 76 70 32</phone>
      <email>ctchikladze@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Claire Toffart, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Moro-Sibilot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matteo Giaj Levra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolomic</keyword>
  <keyword>Microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

